- Nuvectis Pharma's NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Lines
- Nuvectis Pharma Announces Upcoming Presentations at the 2024 American Association for Cancer Research Meeting
- Nuvectis Pharma to Present at the 36th Annual Roth Conference
- Nuvectis Pharma Announces Encouraging Preliminary Data from the NXP800 Phase 1b Clinical Trial in Platinum-Resistant ARID1a-Mutated Ovarian Cancer
- Correction: Nuvectis Pharma Announces Participation at Upcoming Investor Conferences
- Nuvectis Pharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Nuvectis Pharma, Inc. Announces a Collaboration with Mayo Clinic to Evaluate NXP800 in an Investigator-Sponsored Clinical Trial in Cholangiocarcinoma
- Nuvectis Pharma Announces Upcoming Poster Presentation for NXP800 at the 2023 AACR Special Conference on Endometrial Cancer
- Nuvectis Pharma Announces Updated Date and Time for the 2023 Cantor Global Healthcare Conference Corporate Presentation
- Nuvectis Pharma Announces Upcoming Presentations for NXP800 and NXP900
More ▼
Key statistics
On Friday, Nuvectis Pharma Inc (NVCT:NAQ) closed at 6.50, 4.84% above its 52-week low of 6.20, set on Jan 23, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 6.52 |
---|---|
High | 6.61 |
Low | 6.43 |
Bid | 6.04 |
Offer | 9.84 |
Previous close | 6.51 |
Average volume | 59.71k |
---|---|
Shares outstanding | 17.77m |
Free float | 7.60m |
P/E (TTM) | -- |
Market cap | 115.50m USD |
EPS (TTM) | -1.42 USD |
Data delayed at least 15 minutes, as of Apr 26 2024 21:00 BST.
More ▼